Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.
Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.
Pliant Therapeutics (Nasdaq: PLRX) reported its Q3 2020 results, highlighting significant progress in clinical programs despite COVID-19 challenges. The company successfully executed its IPO and advanced multiple indications in its pipeline, notably PLN-74809 for idiopathic pulmonary fibrosis and COVID-19 related ARDS. Financially, the company experienced related party revenue of $4.8 million, with R&D expenses rising to $16.9 million, leading to a net loss of $16.5 million. Pliant maintains a strong cash position of $294 million, sufficient to fund operations into 2023.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) will present a poster at The Liver Meeting® 2020, hosted by AASLD, from November 13-16, 2020. The poster, titled "Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis" (Abstract #0321), will be available online for registered participants. Pliant, focused on fibrosis treatment, has two main candidates: PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and PLN-1474, in Phase 1 trials for liver fibrosis associated with NASH.
Pliant Therapeutics (Nasdaq: PLRX) has appointed Mike Ouimette as the new general counsel and corporate secretary. Bringing over 20 years of legal expertise, Ouimette previously held executive positions at Portola Pharmaceuticals and Onyx Pharmaceuticals. His appointment aims to enhance Pliant's legal and regulatory strategies as the company progresses its lead drug candidate, PLN-74809, through Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Pliant focuses on developing innovative therapies for treating fibrosis.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its data presentation on PLN-74809 during the ATS 2020 Virtual Sessions on Sept. 24, 2020. PLN-74809 is an oral dual selective integrin inhibitor being evaluated for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The treatment has received Orphan Drug Designation by the FDA for both indications and is currently in Phase 2a trials for IPF and PSC. The presentation will be accessible to registered attendees until Nov. 10, 2020.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology firm specializing in fibrosis treatments, will participate in investor conferences during September 2020. Key events include Citi's 15th Annual BioPharma Conference from September 8-11, where Scott Turner, Ph.D., will discuss COVID-19 therapeutics on September 9 at 9:50 a.m. EDT. Additionally, the company will attend Cantor Fitzgerald's Virtual Global Healthcare Conference from September 15-17. More details and access to presentations can be found on the Pliant Therapeutics Investors page.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its participation in The Digital International Liver Congress 2020, showcasing data on PLN-74809 for treating fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The oral presentation highlights PLN-74809 as a dual integrin inhibitor that reduces fibrosis in preclinical models. Additionally, a poster presentation will discuss collagen gene expression reduction in liver tissue from cirrhotic patients. Pliant is in Phase 2a trials for PLN-74809 and is also developing PLN-1474 for liver fibrosis related to nonalcoholic steatohepatitis (NASH).
Pliant Therapeutics, Inc. (PLRX) reported strong progress in its fibrosis treatment pipeline, highlighting the initiation of a Phase 2a trial for PLN-74809 in idiopathic pulmonary fibrosis, along with advancements in its partnership with Novartis for PLN-1474. The company completed a successful IPO, raising $165.6 million, with an additional $10 million from Novartis. Financial results showed second-quarter related party revenue of $3.6 million and a net loss of $17 million. Pliant holds $312.5 million in cash, ensuring operational stability through 2023.